Boyle Kimberly L, Leech Elizabeth
VCA All-Care Animal Referral Center, Fountain Valley, CA, 92708, USA.
J Vet Emerg Crit Care (San Antonio). 2012 Aug;22(4):398-408. doi: 10.1111/j.1476-4431.2012.00768.x.
To review the pharmacology, research developments, and clinical uses of pimobendan
Original research articles and clinical studies from 1984 to August 2011.
Pimobendan is approved for use in dogs for the treatment of congestive heart failure (CHF) secondary to chronic valvular heart disease (CVHD) and dilated cardiomyopathy (DCM). Expert-based veterinary guidelines recommend the use of pimobendan in the management of acute, hospital-based therapy for patients with CHF attributable to CVHD.
The use of pimobendan, an inodilator with phosphodiesterase 3 (PDE3) inhibitory and calcium-sensitizing properties, is regarded as a component of the standard of care in the management of dogs with CHF secondary to both DCM and CVHD. Further studies are warranted to confirm the safety and efficacy of pimobendan for the off-label use of this drug in asymptomatic CVHD, pulmonary arterial hypertension, asymptomatic myocardial diseases, CHF from all other causes and in cats with CHF.
综述匹莫苯丹的药理学、研究进展及临床应用
1984年至2011年8月的原创研究文章和临床研究
匹莫苯丹已获批用于犬，治疗继发于慢性瓣膜性心脏病（CVHD）和扩张型心肌病（DCM）的充血性心力衰竭（CHF）。基于专家的兽医学指南推荐在因CVHD导致CHF的患者急性住院治疗中使用匹莫苯丹。
匹莫苯丹是一种具有磷酸二酯酶3（PDE3）抑制和钙增敏特性的血管扩张剂，被视为治疗继发于DCM和CVHD的犬CHF标准治疗方案的一部分。有必要进一步研究以证实匹莫苯丹用于无症状CVHD、肺动脉高压、无症状心肌疾病、所有其他原因导致的CHF以及猫CHF时该药物的非标签使用的安全性和有效性。
